INTENSITY THERAPEUTICS, INC. Logo

INTENSITY THERAPEUTICS, INC.

Develops injected therapies to kill tumors locally and activate a systemic immune response.

INTS | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1 ENTERPRISE DRIVE, SUITE 430, 6484 SHELTON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company developing a novel, immune-based approach to treat solid tumor cancers. The company's proprietary DfuseRx℠ technology platform enables the direct intratumoral injection of therapeutic agents. This 'treat locally, act globally' method is designed to kill cancer cells within the injected tumor while simultaneously activating a systemic, antigen-specific immune response to attack metastatic sites throughout the body. Its lead product candidate, INT230-6, is being evaluated in clinical trials for various cancers, including breast cancer and sarcomas. The company's mission is to extend patient survival and improve quality of life while preventing disease recurrence.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all INTENSITY THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for INTENSITY THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for INTENSITY THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America FDMT
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
Abivax S.A. Logo
Biotech developing oral drugs for chronic inflammatory diseases like colitis and Crohn's.
United States of America ABVX
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America ABSI
ABVC BIOPHARMA, INC. Logo
Develops plant-based drugs and medical devices for CNS, oncology, and ophthalmic disorders.
United States of America ABVC

Talk to a Data Expert

Have a question? We'll get back to you promptly.